Many cancers harbor pro-proliferative mutations of the mitogen-activated protein kinase (MAPK) pathway. In BRAF-driven melanoma cells treated with BRAF inhibitors, subpopulations of cells escape ...
Gomekli showed an 87% overall response rate in pediatric low-grade glioma with MAPK pathway activation, with a recommended ...
Promising preliminary monotherapy data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in advanced solid tumors, which had favorable safety, tolerability, and efficacy profiles that support ...
The effective targeting of RAS-mutant acute myeloid leukemia (AML) still remains a challenge; RAS mutations are tied to relapse to targeted therapy, such as resistance to FLT3 inhibitors due to the ...
Psoriasis is characterized by hyperproliferation of keratinocytes and increased expression of integrins, but the pathological signaling pathway remains unknown. In August 15 Journal of Clinical ...
Non-V600 mutations comprise approximately 35% of all BRAF mutations in cancer. Many of these mutations have been identified as oncogenic drivers and can be classified into three classes according to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback